Seth Klarman acquired 11.4 Million Theravance Biopharma shares worth $120 Million. That's 1.92% of their equity portfolio (17th largest holding). The investor owns 18.38% of the outstanding Theravance Biopharma stock. The first Theravance Biopharma trade was made in Q2 2014. Since then Seth Klarman bought shares eight more times and sold shares on four occasions. The investor's estimated purchase price is $267 Million, resulting in a loss of 55%.